PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
← catalyst calendarSponsored by Prelude Therapeutics (industry) · PRLD — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
135actual
Sites
32
Countries
France, Netherlands, Singapore +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-02 | actual | When the study began enrolling |
| Primary completion | 2025-10-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-01 | actual | The whole study's end, after follow-up |
| First posted | 2022-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Non-small Cell Lung Cancers
- SMARCA4 Gene Mutation
Interventions
- Drug: PRT3789
- Drug: Docetaxel
Primary outcomes
what the primary-completion date above is the date OFDose limiting toxicity (DLT) of PRT3789 monotherapy and in combination with docetaxel
measured Baseline through Day 21
Safety and tolerability of PRT3789 monotherapy and in combination with docetaxel: AEs, CTCAE Assessments
measured Baseline through approximately 3 years
Maximum tolerated dose (MTD)/ Recommended phase 2 dose (RP2D) of PRT3789 monotherapy and in combination with docetaxel
measured Baseline through approximately 3 years
Permalink · PRLD's whole pipeline · Catalyst calendar · Every registered study · What changed